ChemoCentryx to Present at Two Upcoming Investor Conferences
On-demand presentation available beginning
A live audio webcast of the Evercore presentation and the on-demand
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally administered therapies. ChemoCentryx’s lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration, along with a Marketing Authorization Application by the
ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.
Executive Vice President,
Chief Financial and Administrative Officer
Source: ChemoCentryx, Inc.